HRP20090076A2 - Antivirusni fosfinatni spojevi - Google Patents

Antivirusni fosfinatni spojevi

Info

Publication number
HRP20090076A2
HRP20090076A2 HR20090076A HRP20090076A HRP20090076A2 HR P20090076 A2 HRP20090076 A2 HR P20090076A2 HR 20090076 A HR20090076 A HR 20090076A HR P20090076 A HRP20090076 A HR P20090076A HR P20090076 A2 HRP20090076 A2 HR P20090076A2
Authority
HR
Croatia
Prior art keywords
virus
compounds
phosphinate compounds
phosphinate
phosphinates
Prior art date
Application number
HR20090076A
Other languages
English (en)
Croatian (hr)
Inventor
Casarez Anthony
Chaudhary Kleem
Cho Aesop
Clarke Michael
Doerffler Edward
Fardis Maria
U. Kim Choung
Pyun Hyungjung
C Sheng Xiaoning
Wang Jianying
Original Assignee
Gilead Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences filed Critical Gilead Sciences
Publication of HRP20090076A2 publication Critical patent/HRP20090076A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HR20090076A 2006-07-07 2007-07-06 Antivirusni fosfinatni spojevi HRP20090076A2 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81948806P 2006-07-07 2006-07-07
US83290806P 2006-07-24 2006-07-24
PCT/US2007/015664 WO2008005565A2 (en) 2006-07-07 2007-07-06 Antiviral phosphinate compounds

Publications (1)

Publication Number Publication Date
HRP20090076A2 true HRP20090076A2 (hr) 2009-05-31

Family

ID=38626760

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090076A HRP20090076A2 (hr) 2006-07-07 2007-07-06 Antivirusni fosfinatni spojevi

Country Status (19)

Country Link
US (4) US7893264B2 (de)
EP (2) EP2422791B1 (de)
JP (3) JP2009542698A (de)
KR (1) KR20090026216A (de)
CN (1) CN102532198A (de)
AR (1) AR061840A1 (de)
AT (1) ATE554776T1 (de)
AU (1) AU2007269567B2 (de)
BR (1) BRPI0713961A2 (de)
CA (1) CA2656356C (de)
EA (1) EA018098B1 (de)
ES (2) ES2388969T3 (de)
HR (1) HRP20090076A2 (de)
IL (1) IL195489A0 (de)
MX (1) MX2009000236A (de)
NO (1) NO20090596L (de)
TW (1) TW200819460A (de)
WO (1) WO2008005565A2 (de)
ZA (1) ZA200810400B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US7893264B2 (en) 2006-07-07 2011-02-22 Gilead Sciences, Inc. Antiviral phosphinate compounds
WO2009142842A2 (en) * 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
WO2010101967A2 (en) * 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
TW201111381A (en) * 2009-06-23 2011-04-01 Gilead Sciences Inc Pharmaceutical combinations useful for treating HCV
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US20110306541A1 (en) * 2010-06-10 2011-12-15 Gilead Sciences, Inc. Methods for treating hcv
TW201306841A (zh) * 2010-12-20 2013-02-16 Gilead Sciences Inc 治療ｃ型肝炎病毒（ｈｃｖ）之方法
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
HRP20180237T4 (hr) 2011-09-16 2020-12-11 Gilead Pharmasset Llc Metode za liječenje hcv-a
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
EP2914613B1 (de) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Inhibitoren des hepatitis-c-virus
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (de) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Inhibitoren des hepatitis-c-virus
EP2950786B1 (de) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Kombinationsformulierung zweier antiviraler verbindungen
EP2964664B1 (de) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hemmer des hepatitis-c-virus
CN103539831B (zh) * 2013-09-29 2016-02-03 北京林业大学 山杏α-葡萄糖苷酶抑制肽及其制备方法和用途
CN103539833B (zh) * 2013-09-29 2016-02-03 北京林业大学 高活性α-葡萄糖苷酶抑制肽及其制备方法和用途
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
ES2969239T3 (es) 2016-05-27 2024-05-17 Gilead Sciences Inc Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
DK0481214T3 (da) 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
DE4308096A1 (de) 1993-03-13 1994-09-15 Hoechst Ag Prodrug-Derivate von Enzyminhibitoren mit Hydroxylgruppen, Verfahren zu deren Herstellung und ihre Verwendung
DE69426904T2 (de) 1993-06-29 2001-10-11 Mitsubishi Chemical Corp., Tokio/Tokyo Phosphonat-Nukleotid Ester-Derivate
ATE486882T1 (de) 1993-09-17 2010-11-15 Gilead Sciences Inc Nukleotidanaloge
JPH07183249A (ja) 1993-12-22 1995-07-21 Nec Yamagata Ltd イオン注入工程管理方法
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5968788A (en) * 1995-08-28 1999-10-19 Toray Industries, Inc. Method for producing folic acid
US6004977A (en) * 1996-12-27 1999-12-21 Hoechst Marion Roussel, Inc. N-(pyridinylamino) isoindolines and related compounds
DE19843360A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Phosphororganische Verbindungen und ihre Verwendung
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
ATE422895T1 (de) 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
KR20070034119A (ko) * 2004-07-16 2007-03-27 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
CN101193862B (zh) * 2005-04-13 2013-08-21 阿斯特克斯治疗有限公司 羟基苯甲酰胺衍生物和其作为hsp90抑制剂的用途
EP2305696A3 (de) * 2005-07-25 2011-10-12 Intermune, Inc. Makrocyclische Inhibitoren der Replikation des Hepatitis-C-Virus
WO2007014922A1 (en) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7893264B2 (en) 2006-07-07 2011-02-22 Gilead Sciences, Inc. Antiviral phosphinate compounds
US8293705B2 (en) * 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
TW201111381A (en) * 2009-06-23 2011-04-01 Gilead Sciences Inc Pharmaceutical combinations useful for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
EP2043658B1 (de) 2012-04-25
JP6010640B2 (ja) 2016-10-19
WO2008005565A3 (en) 2008-05-02
US20080057031A1 (en) 2008-03-06
WO2008005565A2 (en) 2008-01-10
CN102532198A (zh) 2012-07-04
IL195489A0 (en) 2009-09-01
AR061840A1 (es) 2008-09-24
AU2007269567A1 (en) 2008-01-10
AU2007269567B2 (en) 2012-11-08
EP2422791B1 (de) 2014-12-17
HK1127295A1 (en) 2009-09-25
KR20090026216A (ko) 2009-03-11
EP2422791A1 (de) 2012-02-29
WO2008005565A9 (en) 2009-01-29
JP2015083605A (ja) 2015-04-30
ATE554776T1 (de) 2012-05-15
ES2388969T3 (es) 2012-10-22
ES2531315T3 (es) 2015-03-12
EP2043658A2 (de) 2009-04-08
US20090227491A1 (en) 2009-09-10
JP2009542698A (ja) 2009-12-03
CA2656356A1 (en) 2008-01-10
US7893264B2 (en) 2011-02-22
JP2012107061A (ja) 2012-06-07
CA2656356C (en) 2013-04-09
EA200900154A1 (ru) 2009-06-30
ZA200810400B (en) 2011-12-28
EA018098B1 (ru) 2013-05-30
US20110081314A1 (en) 2011-04-07
US20110082112A1 (en) 2011-04-07
NO20090596L (no) 2009-04-01
BRPI0713961A2 (pt) 2012-11-27
US8586744B2 (en) 2013-11-19
MX2009000236A (es) 2009-01-23
TW200819460A (en) 2008-05-01
US8674088B2 (en) 2014-03-18

Similar Documents

Publication Publication Date Title
HRP20070043A2 (hr) Antivirusna sredstva
HRP20070078A2 (hr) Fosfonatni analozi spojeva koji inhibiraju hiv
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
EA201490132A1 (ru) Противовирусные соединения
CY1119684T1 (el) Αντι-ιικες ενωσεις
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA200971074A1 (ru) Антивирусные соединения
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
WO2008005565A3 (en) Antiviral phosphinate compounds
EA201190306A1 (ru) Улучшенная липидная композиция
ATE543854T1 (de) Neue polycarbonat-polyorganosiloxan- und/oder polyurethan-polyorganosiloxan-verbindungen
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
ECSP088854A (es) Moduladores bencimidazolicos de vr1
EA200870514A1 (ru) Ацетиленовые гетероарильные соединения
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
EA200702329A1 (ru) Замещенные пирролпиридины, содержащие их композиции, способ получения и применение
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
SG158091A1 (en) Imidazoazepinone compounds

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20130624

Year of fee payment: 7

OBST Application withdrawn